183720-17-4

Basic information

• Product Name: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one
• Synonyms: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one
• CAS NO: 183720-17-4
• Molecular Weight: 343.69
• Mol File: 183720-17-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one(183720-17-4)
• EPA Substance Registry System: 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one(183720-17-4)

Safety Data

• Hazardous Substances Data: 183720-17-4(Hazardous Substances Data)

Upstream product

• 183720-15-2 3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one 
• 343-69-1 6-(Trifluoromethyl)-1H-indol-2,3-dione 
• 106-48-9 4-chloro-phenol 

Relevant articles and documents

Reactivity and regioselectivity of magnesium phenolates towards isatins: One-step synthesis of 3-(2-hydroxyaryl)-3-hydroxyindolones

A variety of aryloxymagnesium bromides react with isatins under extremely mild conditions to provide 3-(2-hydroxyaryl)-3-hydroxyindolones in good yield. The main features of this protocol consist of exceptionally selective ortho-C-alkylation of the ambident phenolate anion and the lack of diarylated products. Moreover, aryloxymagnesium bromides derived from meta- substituted phenols react with isatins exclusively at the sterically less hindered ortho-position of the phenol.

Methods for treating hyperactive gastric motility

This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Among the preferred compounds of this invention is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also referred to as retigabine.

Synthesis and structure-activity relationships of 3-aryloxindoles: A new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties

A series of 3-aryloxindole derivatives were synthesized and evaluated as activators of the cloned maxi-K channel mSlo expressed in Xenopus laevis oocytes using electrophysiological methods. The most promising maxi-K openers to emerge from this study were